Weisman Leonard E
Baylor College of Medicine, and, Perinatal Center, Texas Children's Hospital, Houston, TX 77030, USA.
Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):223-33. doi: 10.2174/187152509789105471.
Respiratory syncytial virus (RSV) is a very important pathogen worldwide. It occurs and recurs naturally throughout life. Both short and long term morbidity, and mortality are particularly significant for infants, especially those infants with underlying conditions and risk factors. Current treatment strategies for these patients (e.g Ribavirin) are limited but several new interventions (e.g. RSV604, BTA9881, ALN-RSV01) are under investigation. Several preventive agents and strategies have been developed (e.g. RSV-IGIV, palivizumab) and others are in the pipeline (e.g. motavizumab) and under development (e,g, Medi-557). In this article, we review the RSV clinical condition with a focus on the highest risk populations. In addition we review prevention and treatment strategies of the past, present and future for these high-risk patients. This review should provide a single valuable source of information to clinicians and investigators.
呼吸道合胞病毒（RSV）是全球范围内一种非常重要的病原体。它在人的一生中自然发生并反复出现。短期和长期的发病率以及死亡率对婴儿来说尤为显著，尤其是那些有基础疾病和风险因素的婴儿。目前针对这些患者的治疗策略（如利巴韦林）有限，但几种新的干预措施（如RSV604、BTA9881、ALN-RSV01）正在研究中。已经开发了几种预防药物和策略（如呼吸道合胞病毒免疫球蛋白静脉注射剂、帕利珠单抗），其他的也在研发中（如莫他珠单抗）以及处于开发阶段（如Medi-557）。在本文中，我们重点针对最高风险人群回顾呼吸道合胞病毒的临床情况。此外，我们还回顾了这些高危患者过去、现在和未来的预防和治疗策略。这篇综述应为临床医生和研究人员提供一个有价值的单一信息来源。
